Pfizer Signs Teuto And Biocon Deals

BMI View: With a number of blockbuster drugs expected to lose patent protection by 2015, Pfizer's aggressive expansion efforts - in the generic and biosimilar drug market segments of high-growth emerging regions - mean that the US drugmaker will be well-positioned to benefit from early-mover advantage and maximise its long-term revenue generating

To read the full article, please choose one of the following options: